Ferring Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for FERRING, and when can generic versions of FERRING drugs launch?
FERRING has seventeen approved drugs.
There are twenty-three US patents protecting FERRING drugs.
There are two hundred and seventy-three patent family members on FERRING drugs in forty countries and twenty supplementary protection certificates in ten countries.
Summary for Ferring
International Patents: | 273 |
US Patents: | 23 |
Tradenames: | 17 |
Ingredients: | 8 |
NDAs: | 17 |
Patent Litigation for Ferring: | See patent lawsuits for Ferring |
Drugs and US Patents for Ferring
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ferring | FIRMAGON | degarelix acetate | POWDER;SUBCUTANEOUS | 022201-001 | Dec 24, 2008 | RX | Yes | No | 10,695,398 | See Plans and Pricing | See Plans and Pricing | ||||
Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-001 | Jun 21, 2018 | RX | Yes | No | 7,947,654 | See Plans and Pricing | Y | See Plans and Pricing | |||
Ferring | DESMOPRESSIN ACETATE | desmopressin acetate | TABLET;ORAL | 021795-001 | May 8, 2008 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
Ferring | FIRMAGON | degarelix acetate | POWDER;SUBCUTANEOUS | 022201-002 | Dec 24, 2008 | RX | Yes | Yes | 10,729,739 | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ferring
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ferring Pharms Inc | DDAVP | desmopressin acetate | INJECTABLE;INJECTION | 018938-001 | Mar 30, 1984 | 5,500,413 | See Plans and Pricing |
Ferring Pharms Inc | DDAVP | desmopressin acetate | SOLUTION;NASAL | 017922-001 | Approved Prior to Jan 1, 1982 | 5,500,413 | See Plans and Pricing |
Ferring Pharms Inc | DDAVP | desmopressin acetate | TABLET;ORAL | 019955-001 | Sep 6, 1995 | 5,047,398 | See Plans and Pricing |
Ferring | THYREL TRH | protirelin | INJECTABLE;INJECTION | 018087-001 | Approved Prior to Jan 1, 1982 | 3,746,697 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FERRING drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Solution | 10 mg, 3.5 g, and12 g | ➤ Subscribe | 2019-02-11 |
➤ Subscribe | Oral Solution | 10 mg, 3.5 g, and 12 g | ➤ Subscribe | 2014-05-21 |
International Patents for Ferring Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Uruguay | 27683 | See Plans and Pricing |
Croatia | P20150290 | See Plans and Pricing |
Portugal | 3225250 | See Plans and Pricing |
European Patent Office | 2249859 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ferring Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1003774 | C01003774/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: DEGARELIX; REGISTRATION NUMBER/DATE: SWISSMEDIC 59455 12.02.2010 |
2782584 | 2021C/558 | Belgium | See Plans and Pricing | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17--ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406 |
2712622 | C02712622/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018 |
2782584 | LUC00245 | Luxembourg | See Plans and Pricing | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.